Sofia Carrilho Vaz
Specialist in Nuclear Medicine
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (14)
Year:
2025
Year:
2025
Background The second most common breast cancer subtype is invasive lobular cancer (ILC). Its locoregional staging is challenging, even when using breast MRI. Different non-[ 18 F]FDG PET tracers have been explored in these patients, and promising results were reported with [ 18 F]FACBC. Nevertheless, no publications directly comparing breast MRI and [ 18 F]FACBC PET are available. Aim To compare the performance of prone [ 18 F]FACBC PET/CT and breast MRI for assessing disease extent in the breast and for depicting lymph node metastases in patients with locally advanced ILC. Methods Retrospective selection of case series of patients with proven locally advanced luminal-like ILC, who underwent both breast MRI and prone [ 18 F]FACBC PET/CT, according to the local clinical standards. Results Eight patients were included. [ 18 F]FACBC PET/CT performed similarly to MRI in T-staging and outperformed MRI in N-staging, especially outside axillary level I/II. [ 18 F]FACBC uptake in the index breast lesion was on average 9 times higher than the breast background. Among the 6 patients submitted to surgery, [ 18 F]FACBC provided the correct T&N staging in 5 patients, confirmed by pathology. Conclusion This initial descriptive case series suggests that prone [ 18 F]FACBC PET/CT could be a valuable imaging tool for both local and regional staging of low-grade luminal-like ILC. A larger prospective clinical trial is needed to further evaluate this potential application.
Year:
2025
Purpose: Nipple discharge is the third most common breast-related complaint. It is recommended to exclude malignancy in pathologic nipple discharge (PND). Mammography and ultrasound are the first-line conventional diagnostic (CD) imaging. Although magnetic resonance is often used as a complementary modality, molecular breast imaging (MBI) with Tc-99m sestamibi may be a suitable alternative. Considering the lack of information on this subject and its clinical importance, this study aimed to evaluate the role of MBI in ruling out malignancy in patients with PND and negative/indeterminate CD. Patients and Methods: Retrospective cohort single-center study including all patients with PND evaluated by CD and MBI between 2012 and 2020. Pathology was considered the gold standard. Follow-up was used when pathology was not available. Results: Of the 96 cases of PND included, 78 were benign, and 18 (20%) corresponded to breast cancer (BC). Although CD and MBI were concordant in the BIRADS classification in 81% (78/96), half of BC were detected by MBI only. BC was located directly behind the nipple in a minority of patients (11%), meaning that MBI could significantly prevent futile central ductal excision. MBI presented higher sensitivity (83% vs. 33%) and negative predictive value (96% vs. 86%) than CD alone, with similar specificity (89% vs. 92%) and positive predictive value (63% vs. 50%). The area under the curve of MBI and CD was 0.86 ( P -value<0.001 [95% CI: 0.75–0.97]) and 0.63 ( P -value=0.091 [95% CI: 0.47-0.79]), respectively. Conclusions: MBI showed good diagnostic accuracy for detecting BC in patients with PND with negative/indeterminate findings on CD imaging.
Year:
2025
Introduction There is much literature about the role of 2-[ 18 F]FDG PET/CT in patients with breast cancer (BC). However, there exists no international guideline with involvement of the nuclear medicine societies about this subject. Purpose To provide an organized, international, state-of-the-art, and multidisciplinary guideline, led by experts of two nuclear medicine societies (EANM and SNMMI) and representation of important societies in the field of BC (ACR, ESSO, ESTRO, EUSOBI/ESR, and EUSOMA). Methods Literature review and expert discussion were performed with the aim of collecting updated information regarding the role of 2-[ 18 F]FDG PET/CT in patients with no special type (NST) BC and summarizing its indications according to scientific evidence. Recommendations were scored according to the National Institute for Health and Care Excellence (NICE) criteria. Results Quantitative PET features (SUV, MTV, TLG) are valuable prognostic parameters. In baseline staging, 2-[ 18 F]FDG PET/CT plays a role from stage IIB through stage IV. When assessing response to therapy, 2-[ 18 F]FDG PET/CT should be performed on certified scanners, and reported either according to PERCIST, EORTC PET, or EANM immunotherapy response criteria, as appropriate. 2-[ 18 F]FDG PET/CT may be useful to assess early metabolic response, particularly in non-metastatic triple-negative and HER2+ tumours. 2-[ 18 F]FDG PET/CT is useful to detect the site and extent of recurrence when conventional imaging methods are equivocal and when there is clinical and/or laboratorial suspicion of relapse. Recent developments are promising. Conclusion 2-[ 18 F]FDG PET/CT is extremely useful in BC management, as supported by extensive evidence of its utility compared to other imaging modalities in several clinical scenarios.
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Collaborators (8)
Francisco Oliveira
Researcher
Champalimaud Foundation
Lioe-Fee de Geus-Oei
Leiden University Medical Center
Lidija Antunovic
Deputy director
IRCCS Humanitas Research Hospital
Felix M. Mottaghy
Head of department
RWTH Aachen University
Jelle J Goeman
Leiden University Medical Center
Françoise Kraeber-Bodéré
MD PhD / Head of department
Centre Hospitalier Universitaire de Nantes
Francesca Serani
Ricercatori a tempo determinato
University of Padova
Gary Cook
King’s College London
Make your next move.
Prepare your application
Review drafts before you send them.